Daily Stock Analysis, CHRS, Coherus BioSciences Inc, priceseries

Coherus BioSciences Inc. Daily Stock Analysis
Stock Information
Open
9.15
Close
9.15
High
9.55
Low
9.10
Previous Close
9.13
Daily Price Gain
0.02
YTD High
14.50
YTD High Date
Jan 12, 2018
YTD Low
8.70
YTD Low Date
Jan 2, 2018
YTD Price Change
-0.40
YTD Gain
-4.19%
52 Week High
26.55
52 Week High Date
Mar 2, 2017
52 Week Low
8.05
52 Week Low Date
Nov 20, 2017
52 Week Price Change
-12.50
52 Week Gain
-57.74%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 27. 2017
22.90
Mar 8. 2017
24.15
7 Trading Days
5.47%
Link
LONG
Jan 2. 2018
9.55
Jan 17. 2018
12.23
10 Trading Days
28.01%
Link
Company Information
Stock Symbol
CHRS
Exchange
NasdaqGM
Company URL
http://www.coherus.com
Company Phone
(650) 649-3530
CEO
Denny M. Lanfear
Headquarters
California
Business Address
C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA 94065
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001512762
About

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company, which engages in the development and commercializition of biosimilar therapeutics worldwide. It focuses on global biosimilar market. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar, and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Description

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, nonsmall cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behcet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.